EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

Summary

Primary objective : To identify epigenetic dysregulations of in vivo TKI-resisting CML cells Hypothesis : An epigenetic dysregulation is involved in the in vivo survival of a CML cell subclone despite the use of TKIs

Conditions

• Chronic Myeloid Leukemia (CML)
• Chronic Phase

Interventions

BIOLOGICAL

Collection of blood and bone marrow

Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment

Sponsors & Collaborators

• Institut Paoli-Calmettes

  collaborator OTHER

• CHRU Lille, hematology department

  collaborator UNKNOWN

• CH Annecy Genevois

  collaborator OTHER

• Institut Bergonié Bordeaux, hematology department

  collaborator UNKNOWN

• Central Hospital, Nancy, France

  collaborator OTHER

• CHU Saint-Etienne, hematology department

  collaborator UNKNOWN

• Institut Universitaire du Cancer de Toulouse

  collaborator OTHER

• CHU Caen, hematology department

  collaborator UNKNOWN

• CHU Nice, hematology department

  collaborator UNKNOWN

• Hospices Civils de Lyon

  collaborator OTHER

• AP-HP, hematology department

  collaborator UNKNOWN

• AP-HP Hôpital Henri-Mondor, hematology department

  collaborator UNKNOWN

• Versailles Hospital

  collaborator OTHER

• Centre Leon Berard

  collaborator OTHER

• University Hospital, Grenoble

  collaborator OTHER

• University Hospital, Clermont-Ferrand

  lead OTHER

Principal Investigators

• Marc BERGER · University Hospital, Clermont-Ferrand

Study Design

Allocation

NA

Purpose

OTHER

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-02-01

Primary Completion

2025-05-01

Completion

2026-02-01

Countries

• France

Study Locations